Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, dose-response study by Michelson D, Faries D, Wernicke J, Kelsey D, Kendrick K, Sallee F R, Spencer T, Atomoxetine ADHD Study Group in Pediatrics (2001). PubMed

Abstract

Atomoxetine is an investigational, nonstimulant pharmacotherapy being studied as potential treatment for attention-deficit/hyperactivity disorder (ADHD). It is thought to act via blockade of the presynaptic norepinephrine transporter in the brain. We assessed the efficacy of 3 doses of atomoxetine compared with placebo in children and adolescents with ADHD.

[ hide abstract ]

Discussed In Paper

Related In Paper

Variant Annotations

None.